Showing results (21-30 of 44) with videos related to

Sort By:
Pageof 5
BMC Cancer|March 26, 2024
Investigator choice of standard therapy versus sequential novel therapy arms in the treatment of relapsed follicular lymphoma (REFRACT): study protocol for a multi-centre, open-label, randomised, phase II platform trialGraham McIlroy, Siân Lax, Charlotte Gaskell, et al.
Journal of Clinical Medicine|October 18, 2018
Drug-Induced Interstitial Lung Disease: A Systematic ReviewSarah Skeoch, Nicholas Weatherley, Andrew J Swift, et al.
Blood Advances|June 5, 2025
Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab, or odronextamab in follicular lymphomaAlexey V Danilov, Swetha Kambhampati Thiruvengadam, Kim Linton, et al.
British Journal of Haematology|June 26, 2019
Outcomes of synchronous systemic and central nervous system (CNS) involvement of diffuse large B-cell lymphoma are dictated by the CNS disease: a collaborative study of the Australasian Lymphoma AllianceJoel C Wight, Mimi Yue, Colm Keane, et al.
Blood Advances|July 10, 2026
MRD-negativity by PBMCs and ctDNA confirms deep and durable responses following epcoritamab monotherapy in R/R FLIsil Altintas, Christopher Morehouse, Elena Favaro, et al.
British Journal of Haematology|September 14, 2020
Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response-adapted design in the first-line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY)Adam Gibb, Sarah J Pirrie, Kim Linton, et al.
The Lancet. Haematology|April 30, 2025
Early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma: long-term results of a randomised, phase 3 trialMichael Northend, William Wilson, Kushani Ediriwickrema, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|March 29, 2014
An integrated characterization of serological, pathological, and functional events in doxorubicin-induced cardiotoxicityLaura Cove-Smith, Neil Woodhouse, Adam Hargreaves, et al.
British Journal of Haematology|January 31, 2020
Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B-cell lymphoma of the central nervous system - an international study of feasibility and efficacy in routine clinical practiceElisabeth Schorb, Christopher P Fox, Benjamin Kasenda, et al.
Leukemia & Lymphoma|November 10, 2017
Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie HospitalMary Gleeson, Clare Peckitt, David Cunningham, et al.
Pageof 5